BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 12469273)

  • 1. [Chronic myeloid leukemia--case report].
    Hentrich M; Stoetzer OJ; Salat C; Ledderose G
    Dtsch Med Wochenschr; 2002 Dec; 127(49):2617. PubMed ID: 12469273
    [No Abstract]   [Full Text] [Related]  

  • 2. [Recent progress in therapy for chronic myelogenous leukemia].
    Urabe A
    Gan To Kagaku Ryoho; 1997 Jul; 24(9):1066-73. PubMed ID: 9239158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chronic myeloid leukemia--treatment].
    Stoetzer OJ; Hentrich M; Salat C
    Dtsch Med Wochenschr; 2002 Dec; 127(49):2621-4. PubMed ID: 12469275
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment strategies for chronic myeloid leukemia].
    Jinnai I
    Rinsho Ketsueki; 2005 Jan; 46(1):1-6. PubMed ID: 16708910
    [No Abstract]   [Full Text] [Related]  

  • 5. What is the dose of STI-571 needed to induce a molecular remission in chronic myeloid leukemia?
    Ruiz-Argüelles GJ
    Haematologica; 2002 Mar; 87(3):ELT15. PubMed ID: 11869961
    [No Abstract]   [Full Text] [Related]  

  • 6. [EBM in the treatment of CML].
    Ohnishi K
    Rinsho Ketsueki; 2005 Jun; 46(6):410-7. PubMed ID: 16447722
    [No Abstract]   [Full Text] [Related]  

  • 7. Induction chemotherapy and post-remission imatinib therapy for de Novo BCR-ABL-positive AML.
    Lazarevic V; Golovleva I; Nygren I; Wahlin A
    Am J Hematol; 2006 Jun; 81(6):470-1. PubMed ID: 16680752
    [No Abstract]   [Full Text] [Related]  

  • 8. [Interferon-alpha in the treatment of chronic myeloid leukemia].
    Guilhot F
    Rev Prat; 1999 Mar; 49(5):464-6. PubMed ID: 10358394
    [No Abstract]   [Full Text] [Related]  

  • 9. [Marked reduction of BCR-ABL fusion chromosome positive cells with interferon therapy combined with short-term imatinib in chronic myelogenous leukemia].
    Ajima A; Takayama N; Hasegawa Y; Kojima H; Nagasawa T
    Gan To Kagaku Ryoho; 2003 Nov; 30(12):1997-9. PubMed ID: 14650975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapy of chronic myelogenous leukemia in 2004].
    Hochhaus A; Berger U; Hehlmann R
    Dtsch Med Wochenschr; 2004 Oct; 129(40):2122-7. PubMed ID: 15455305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease.
    Breccia M; Cannella L; Stefanizzi C; Santopietro M; De Cuia R; Diverio D; Alimena G
    Leuk Res; 2009 May; 33(5):645-8. PubMed ID: 19062090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chronic myeloid leukemia: current pathogenetic aspects and new therapeutic approaches (a foreign literature review)].
    Petukhov VI; Strozha IL; Bondare DK
    Ter Arkh; 2001; 73(12):96-101. PubMed ID: 11858124
    [No Abstract]   [Full Text] [Related]  

  • 13. Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature.
    Guastafierro S; Falcone U; Celentano M; Coppola M; Ferrara MG; Sica A
    Leuk Res; 2009 Aug; 33(8):1079-81. PubMed ID: 19167064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STI571 (GLIVEC) induced hematologic, cytogenetic and molecular remission in a cml patient relapsing with accelerated phase after allogeneic stem cell transplantation.
    Consoli U; Milone G; Guido G; Consoli C; Palumbo GA; Giustolisi R
    Haematologica; 2002 Dec; 87(12):ECR37. PubMed ID: 12495908
    [No Abstract]   [Full Text] [Related]  

  • 15. [Cellular immunotherapy in chronic myeloid leukemia].
    Fernández MN
    Sangre (Barc); 1998 Apr; 43(2):164-70. PubMed ID: 9656778
    [No Abstract]   [Full Text] [Related]  

  • 16. [A case of chronic myelogenous leukemia responding to imatinib mesilate (Glivec) after relapse of blastic crisis following allogeneic bone marrow transplantation].
    Fujisawa S; Yano K; Kobayashi M
    Gan To Kagaku Ryoho; 2003 Mar; 30(3):427-30. PubMed ID: 12669406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous stem cells collected after debulking by high dose chemotherapy in late phase chronic myeloid leukemia may improve Imatinib efficacy.
    Kalayoglu-Besisik S; Ozturk GB; Caliskan Y; Nalcaci M; Gurses N; Cin N; Ozbek U; Sargin D
    Transfus Apher Sci; 2007 Feb; 36(1):91-4. PubMed ID: 17222585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unsuccessful allogeneic and autologous transplants after prolonged interferon-alpha treatment in a pediatric patient with chronic myeloid leukemia.
    Pérez-Caballero C; Maldonado MS; Tamariz R; de Oteyza JP; Muñoz A
    Haematologica; 2000 Jan; 85(1):105-6. PubMed ID: 10629605
    [No Abstract]   [Full Text] [Related]  

  • 19. Successful treatment of chronic myeloid leukemia with imatinib mesylate in a patient with chronic renal failure on hemodialysis.
    Ozdemir E; Koc Y; Kansu E
    Am J Hematol; 2006 Jun; 81(6):474. PubMed ID: 16680756
    [No Abstract]   [Full Text] [Related]  

  • 20. [Chronic myeloid leukemia. State of the art, May 1993].
    Hehlmann R
    Schweiz Med Wochenschr; 1994 Jan; 124(1-2):37-43. PubMed ID: 8296189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.